Macrogenics Inc

NASDAQ:MGNX 4:00:00 PM EDT

7.12

-0.12 (-1.66%)

4:09:50 PM EDT: $7.01 -0.11 (-1.55%)

Products

MacroGenics Announces FDA Approval Of Margenza For Patients With Pretreated Metastatic Her2-Positive Breast Cancer

Published: 12/16/2020 21:51 GMT

Macrogenics Inc (MGNX) - Macrogenics Announces FDA Approval of Margenza™ for Patients With Pretreated Metastatic Her2-positive Breast Cancer.
Macrogenics Inc - Product Launch Anticipated in March of 2021.
Macrogenics Inc - Macrogenics Anticipates That Margenza Will Be Available in March of 2021.